Laboratorios Farmaceuticos RoviLABFF 93 Days Sales Outstanding is 98.64 as of Mar. 2026, which is 44% above its 10-year median of 68.61. GuruFocus rates LABFF with a GF Score™ of 93/100 and a GF Value™ of $82.42. The stock has 1 warning sign investors should review. Among 944 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks worse than 53.28% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi Days Sales Outstanding Chart
LABFF vs ZTS, UTHR, VTRS: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Days Sales Outstanding falls into.
Laboratorios Farmaceuticos Rovi Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi (LABFF) has a Days Sales Outstanding of 98.64 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 44% above median its historical median of 68.61. Over the past decade, Laboratorios Farmaceuticos Rovi's Days Sales Outstanding has ranged from 63.74 to 76.31. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #503 out of 944 companies in the Drug Manufacturers industry, placing it in the top 53.3%.
Is Laboratorios Farmaceuticos Rovi's Days Sales Outstanding too high?
Laboratorios Farmaceuticos Rovi's current Days Sales Outstanding of 98.64 is 44% above median its 10-year median of 68.61. Over the past 10 years, this metric has ranged from a low of 63.74 to a high of 76.31. The Drug Manufacturers industry median Days Sales Outstanding is 71.98. Laboratorios Farmaceuticos Rovi's value of 98.64 is 37% above this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #503 out of 944 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Days Sales Outstanding compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #503 out of 944 companies for Days Sales Outstanding. This places Laboratorios Farmaceuticos Rovi in the lower half of its industry. The industry median Days Sales Outstanding is 71.98. Laboratorios Farmaceuticos Rovi's value of 98.64 is 37% above this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own Days Sales Outstanding has ranged from 63.74 to 76.31 over the past decade. While the company's 10-year median is 68.61 vs. the industry median of 71.98, Laboratorios Farmaceuticos Rovi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.98, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current Days Sales Outstanding of 98.64 is 37% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current Days Sales Outstanding is 98.64, which is 44% above median its own 10-year median of 68.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (LABFF) has a current Days Sales Outstanding of 98.64. The stock's GF Value™ is $82.42, compared to a current price of $90.61 — trading 9.9% above its estimated fair value. The current Days Sales Outstanding is 98.64, which is 44% above median its 10-year median of 68.61 and 37% above the Drug Manufacturers industry median of 71.98. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current Days Sales Outstanding is 98.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of $90.61 is trading 9.9% above its estimated GF Value™ of $82.42.
Key valuation signals for LABFF:
Days Sales Outstanding: 98.64 (44% above median its 10-year median of 68.61)
GF Value™: $82.42 vs. price of $90.61 (9.9% above fair value)
Industry Position: 37% above the Drug Manufacturers median (#503 of 944)
No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score
Get the complete analysis for LABFF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABFF has been successfully added to your 
